Broccoli Sprouts: A Concentrated Source of Sulforaphane

Evidence Review

The Landmark Discovery (Fahey, Zhang, and Talalay, 1997)

The clinical story of broccoli sprouts begins with a 1997 paper from the Brassica Chemoprotection Laboratory at Johns Hopkins [1]. Fahey and colleagues screened a wide range of cruciferous vegetables for glucoraphanin content and found that 3-day-old broccoli sprouts contained 10 to 100 times more glucoraphanin per gram than mature broccoli plants. They also confirmed that the sprouts induced the same phase 2 detoxification enzyme activity that had previously been associated with cancer chemoprevention in animal models. This paper launched a substantial body of clinical research and led directly to the commercialization of standardized broccoli sprout extracts. The finding has been independently replicated multiple times.

H. pylori Suppression in a Randomized Human Trial (Yanaka et al., 2009)

Yanaka and colleagues randomized 48 H. pylori-infected individuals to either 70 g/day of broccoli sprouts (containing approximately 420 µmol of glucoraphanin) or alfalfa sprouts as placebo for 8 weeks [2]. The broccoli sprout group showed statistically significant reductions in urea breath test values (reflecting bacterial urease activity), H. pylori stool antigen levels, and serum pepsinogens I and II — biomarkers of chronic gastric mucosal inflammation. All values returned to baseline 8 weeks after the intervention ended. Parallel mouse experiments in the same study showed that the protective effect was abolished when the Nrf2 gene was deleted, confirming that Nrf2 activation is the central mechanism. The study population was entirely Japanese, where H. pylori prevalence and gastric cancer rates are high, which increases the external validity for that population specifically. Limitations include the relatively small sample size and the absence of long-term follow-up.

Air Pollution Detoxification in a Placebo-Controlled Trial (Egner et al., 2014)

A randomized, placebo-controlled trial in Qidong, China — a region with high levels of airborne benzene, acrolein, and other carcinogens from industrial and agricultural pollution — enrolled 291 adults to receive either a broccoli sprout beverage or placebo daily for 12 weeks [3]. The beverage provided approximately 600 µmol of glucoraphanin and 40 µmol of pre-formed sulforaphane per day. Compared to placebo, the intervention group showed significantly higher urinary excretion of mercapturic acid conjugates of benzene (61% increase; P ≤ 0.001) and acrolein (23% increase; P = 0.009) — indicating enhanced enzymatic detoxification of these carcinogens. Effects were dose-dependent and appeared within the first two weeks. This is among the most compelling human trials because it demonstrates a real-world reduction in carcinogen burden in a heavily exposed population. The study does not establish whether this translates to reduced cancer incidence, which would require a much longer follow-up.

Autism Spectrum Disorder: Behavioral Improvements in a Randomized Trial (Singh et al., 2014)

One of the more surprising findings in broccoli sprout research comes from a placebo-controlled, double-blind trial in 44 young men aged 13–27 with moderate to severe autism spectrum disorder [4]. Participants received sulforaphane derived from broccoli sprout extract (50–150 µmol/day, scaled by body weight) or placebo for 18 weeks. At 18 weeks, the sulforaphane group showed significant improvements on the Aberrant Behavior Checklist (ABC scores fell from 62.4 to 45.0; P < 0.001) and the Social Responsiveness Scale (SRS scores fell from 121.5 to 105.2; P < 0.001). Clinician-rated improvement on the CGI-I scale was also significantly better in the sulforaphane group. Behaviors largely returned to baseline after treatment ended at 22 weeks. The authors hypothesize that sulforaphane's effects on heat shock proteins, oxidative stress, and neuroinflammation may partially explain the improvements. Limitations include the small sample, an all-male population, and lack of mechanistic data linking Nrf2 activation directly to the behavioral changes observed. Replication in larger and more diverse populations is needed before clinical recommendations can be made.

Liver Enzyme Reduction in Male Subjects with Fatty Liver (Kikuchi et al., 2015)

Kikuchi and colleagues conducted a randomized, double-blind, placebo-controlled trial in 52 Japanese men with elevated liver enzymes characteristic of fatty liver disease [5]. Participants received broccoli sprout extract capsules containing approximately 69 µmol of glucoraphanin per day or placebo for 2 months. In the glucoraphanin group, serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (γ-GTP) all decreased significantly compared to placebo. Urinary 8-hydroxydeoxyguanosine (8-OHdG), a marker of oxidative DNA damage, also fell significantly, suggesting that reduced oxidative stress is the underlying mechanism. The effect sizes were modest but clinically meaningful: ALT dropped from a mean of approximately 42 to 32 IU/L (a 24% reduction). This trial is limited by its size, short duration, and restriction to Japanese men, but the results are consistent with the Nrf2-mediated antioxidant mechanisms established in other research.

Liver Function in Healthy Adults with High-Normal Biomarkers (Satomi et al., 2022)

Satomi and colleagues extended this line of research to a healthier population — adults who had elevated hepatic biomarkers within the high-normal range rather than frank liver disease [6]. In this randomized, double-blind, placebo-controlled parallel-group trial (n = 70), participants received glucoraphanin-enriched broccoli sprout supplements or placebo. At the end of the intervention, the supplement group showed statistically significant reductions in ALT and γ-GTP compared to placebo. Importantly, the effects were most pronounced in participants who had the highest baseline enzyme levels within the high-normal range, suggesting that broccoli sprout supplementation may be most useful as a preventive measure in people who are trending toward liver stress before disease is established. This trial adds value by demonstrating efficacy in a primary prevention context rather than only in people with existing pathology.

Overall Strength of Evidence

The human evidence for broccoli sprouts is broader and more consistent than for most dietary supplements. The Nrf2 mechanism is well-established and has been independently confirmed across multiple studies in different populations. The strongest evidence is for detoxification of environmental pollutants and suppression of H. pylori. Evidence for liver enzyme reduction is promising but based on relatively small trials. The ASD findings are intriguing but preliminary. What the evidence collectively shows is that broccoli sprouts reliably activate the body's own antioxidant and detoxification machinery — a mechanism with relevance across multiple organ systems and disease contexts.